Doxycycline-like drugs for Alzheimer's and Parkinson's Disease

Pardis Tabae Damavandi

Queen Mary University of London

The copyright © 2021 rests with the author.

Following, the design of three potential alpha-synuclein, tau-protein and beta-amyloid inhibitors for *in vitro* studies. The first molecule is a derivative (Figure 1)..

Figure 1. A doxycycline derivative designed afresh.

The second compound has an oxazole introduction (Figure 2).

Figure 2. The oxazole is introduced.

The last compound is only pathology-specific, thus only works for alpha-synuclein.